What's Happening?
SKAN Group reported a 20.2% increase in order intake to CHF 213.0 million for the first half of 2025, with a record order backlog of CHF 386.4 million. Despite strong demand for its isolator systems, net sales declined by 17.8% due to project postponements in vaccine lines. The acquisition of Metronik d.o.o. aims to enhance SKAN's offerings in the pharmaceutical sector. The company remains optimistic about compensating for temporary shortfalls in the second half of the year, confirming its guidance for 2025.
AD
Why It's Important?
SKAN Group's performance highlights the cyclical nature of the pharmaceutical equipment business, with project delays impacting short-term financial results. The strategic acquisition of Metronik d.o.o. positions SKAN to offer integrated solutions along the pharmaceutical value chain, potentially increasing its market share and competitiveness. This development is significant for stakeholders in the pharmaceutical and biotech industries, as it may influence investment and operational strategies.
What's Next?
SKAN Group plans to leverage its full order books and high-quality pipeline to achieve growth targets in the second half of 2025. The company is evaluating options to expand its presence in the U.S. to ensure stability amid changing trade regulations. The development of Pre-Approved Services is progressing, with commercial operations expected to start in the second half of 2026.
